LFA-1–specific therapy prolongs allograft survival in rhesus macaques
Open Access
- 1 December 2010
- journal article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 120 (12), 4520-4531
- https://doi.org/10.1172/jci43895
Abstract
Outcomes in transplantation have been limited by suboptimal long-term graft survival and toxicities associated with current immunosuppressive approaches. T cell costimulation blockade has shown promise as an alternative strategy to avoid the side effects of conventional immunosuppressive therapies, but targeting CD28-mediated costimulation alone has proven insufficient to prevent graft rejection in primates. Donor-specific memory T (TM) cells have been implicated in costimulation blockade–resistant transplant rejection, due to their enhanced effector function and decreased reliance on costimulatory signaling. Thus, we have tested a potential strategy to overcome TM cell–driven rejection by targeting molecules preferentially expressed on these cells, such as the adhesion molecule lymphocyte function–associated antigen 1 (LFA-1). Here, we show that short-term treatment (i.e., induction therapy) with the LFA-1–specific antibody TS-1/22 in combination with either basiliximab (an IL-2Rα–specific mAb) and sirolimus (a mammalian target of rapamycin inhibitor) or belatacept (a high-affinity variant of the CD28 costimulation–blocker CTLA4Ig) prolonged islet allograft survival in nonhuman primates relative to control treatments. Moreover, TS-1/22 masked LFA-1 on TM cells in vivo and inhibited the generation of alloproliferative and cytokine-producing effector T cells that expressed high levels of LFA-1 in vitro. These results support the use of LFA-1–specific induction therapy to neutralize costimulation blockade–resistant populations of T cells and further evaluation of LFA-1–specific therapeutics for use in transplantation.Keywords
This publication has 45 references indexed in Scilit:
- Experience with a Novel Efalizumab‐Based Immunosuppressive Regimen to Facilitate Single Donor Islet Cell TransplantationAmerican Journal of Transplantation, 2010
- PML problems loom for RituxanNature Biotechnology, 2010
- Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primatesNature Medicine, 2009
- Donor-Reactive T-Cell Stimulation History and Precursor Frequency: Barriers to Tolerance InductionTransplantation, 2009
- Translating costimulation blockade to the clinic: lessons learned from three pathwaysImmunological Reviews, 2009
- Progressive Multifocal Leukoencephalopathy and Use of Mycophenolate Mofetil After Kidney TransplantationTransplantation, 2008
- Intercellular Adhesion Molecule-1-Dependent Stable Interactions between T Cells and Dendritic Cells Determine CD8+ T Cell MemoryImmunity, 2008
- Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin*1Clinical Immunology, 2004
- Targeting LFA-1 Synergizes with CD40/CD40L Blockade for Suppression of Both CD4-Dependent and CD8-Dependent RejectionAmerican Journal of Transplantation, 2003
- A Real Time Quantitative PCR-based Method for the Detection and Quantification of Simian Virus 40Biologicals, 1999